Nuclear mobility and activity of FOXA1 with Androgen Receptor Are Regulated by SUMOylation

Molecular Endocrinology

Volumn 28, Issue 10, 2014, Pages 1719-1728

  Sutinen, Päivi ^a   Rahkama, Vesa ^a   Rytinki, Miia ^a   Palvimo, Jorma J ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; SUMO 1 PROTEIN; SUMO 2 PROTEIN; SUMO 3 PROTEIN; TRANSCRIPTION FACTOR GAL4; FOXA1 PROTEIN, HUMAN; PROTEIN INHIBITOR OF ACTIVATED STAT; PROTEINASE; SENP1 PROTEIN, HUMAN;

ARTICLE; BINDING SITE; CELL NUCLEUS; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CONSENSUS SEQUENCE; CONTROLLED STUDY; COS 1 CELL LINE; DNA BINDING; FEMALE; FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING; GENE EXPRESSION ASSAY; GENE LOCUS; GENE MUTATION; HALF LIFE TIME; HEK293 CELL LINE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LNCAP CELL LINE; MALE; MOLECULAR WEIGHT; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN STABILITY; REPORTER GENE; SUMOYLATION; TRANSACTIVATION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; UBIQUITINATION; ANIMAL; CHLOROCEBUS AETHIOPS; GENETIC TRANSCRIPTION; METABOLISM; PHYSIOLOGY; PROMOTER REGION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL NUCLEUS; CERCOPITHECUS AETHIOPS; COS CELLS; ENDOPEPTIDASES; HEK293 CELLS; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HUMANS; PROMOTER REGIONS, GENETIC; PROTEIN INHIBITORS OF ACTIVATED STAT; RECEPTORS, ANDROGEN; SUMOYLATION; TRANSCRIPTION, GENETIC;

EID: 84907664573     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/me.2014-1035     Document Type: Article

References (43)

1. Flotho A, Melchior F. Sumoylation: A regulatory protein modification in health and disease. Annu Rev Biochem. 2013;82:357-385.
2. Hay RT. SUMO: A history of modification. Mol Cell. 2005;18:1-12.
3. Wilkinson KA, Henley JM. Mechanisms, regulation and consequences of protein SUMOylation. Biochem J. 2010;428:133-145.
4. Matic I, van Hagen M, Schimmel J, et al. In vivo identification of human small ubiquitin-like modifier polymerization sites by high accuracy mass spectrometry and an in vitro to in vivo strategy. Mol Cell Proteomics. 2008;7:132-144.
5. Geiss-Friedlander R, Melchior F. Concepts in sumoylation: A decade on. Nat Rev Mol Cell Biol. 2007;8:947-956.
6. Rytinki MM, Kaikkonen S, Pehkonen P, Jääskeläinen T, Palvimo JJ. PIAS proteins: Pleiotropic interactors associated with SUMO. Cell Mol Life Sci. 2009;66:3029-3041.
7. Kim JH, Baek SH. Emerging roles of desumoylating enzymes. Biochim Biophys Acta. 2009;1792:155-162.
8. Costa RH, Kalinichenko VV, Lim L. Transcription factors in mouse lung development and function. Am J Physiol Lung Cell Mol Physiol. 2001;280:L823-38.
9. Minoo P, Hu L, Zhu N, et al. SMAD3 prevents binding of NKX2.1 and FOXA1 to the SpB promoter through its MH1 and MH2 domains. Nucleic Acids Res. 2008;36:179-188.
10. Kaestner KH. The hepatocyte nuclear factor 3 (HNF3 or FOXA) family in metabolism. Trends Endocrinol Metab. 2000;11:281-285.
11. Kaestner KH. The FoxA factors in organogenesis and differentiation. Curr Opin Genet Dev. 2010;20:527-532.
12. Jozwik KM, Carroll JS. Pioneer factors in hormone-dependent cancers. Nat Rev Cancer. 2012;12:381-385.
13. Jääskeläinen J. Molecular biology of androgen insensitivity. Mol Cell Endocrinol. 2012;352:4-12.
14. Green SM, Mostaghel EA, Nelson PS. Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol. 2012;360:3-13.
15. Saylor PJ. Prostate cancer: The androgen receptor remains front and centre. Nat Rev Clin Oncol. 2013;10:126-128.
16. Albergaria A, Paredes J, Sousa B, et al. Expression of FOXA1 and GATA-3 in breast cancer: The prognostic significance in hormone receptor-negative tumours. Breast Cancer Res. 2009;11:R40.
17. Badve S, Turbin D, Thorat MA, et al. FOXA1 expression in breast cancer—correlation with luminal subtype A and survival. Clin Cancer Res. 2007;13:4415-4421.
18. Sahu B, Laakso M, Ovaska K, et al. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J. 2011;30:3962-3976.
19. Belikov S, Öberg C, Jääskeläinen T, Rahkama V, Palvimo JJ, Wrange O. FoxA1 corrupts the antiandrogenic effect of bicalutamide but only weakly attenuates the effect of MDV3100 (Enzalutamide ™). Mol Cell Endocrinol. 2013;365:95-107.
20. Sahu B, Laakso M, Pihlajamaa P, et al. FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells. Cancer Res. 2013;73:1570-1580.
21. Kotaja N, Karvonen U, Jänne OA, Palvimo JJ. PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases. Mol Cell Biol. 2002;22:5222-5234.
22. Bailey D, O’Hare P. Characterization of the localization and proteolytic activity of the SUMO-specific protease, SENP1. J Biol Chem. 2004;279:692-703.
23. Rytinki M, Kaikkonen S, Sutinen P, Paakinaho V, Rahkama V, Palvimo JJ. Dynamic SUMOylation is linked to the activity cycles of androgen receptor in the cell nucleus. Mol Cell Biol. 2012;32:4195-4205.
24. Ikonen T, Palvimo JJ, Jänne OA. Interaction between the aminoand carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators. J Biol Chem. 1997;272:29821-29828.
25. Thompson J, Lepikhova T, Teixido-Travesa N, Whitehead MA, Palvimo JJ, Jänne OA. Small carboxyl-terminal domain phosphatase 2 attenuates androgen-dependent transcription. EMBO J. 2006;25:2757-2767.
26. Kaikkonen S, Jääskeläinen T, Karvonen U, et al. SUMO-specific protease 1 (SENP1) reverses the hormone-augmented SUMOylation of androgen receptor and modulates gene responses in prostate cancer cells. Mol Endocrinol. 2009;23:292-307.
27. Makkonen H, Kauhanen M, Paakinaho V, Jääskeläinen T, Palvimo JJ. Long-range activation of FKBP51 transcription by the androgen receptor via distal intronic enhancers. Nucleic Acids Res. 2009;37: 4135-4148.
28. Makkonen H, Jääskeläinen T, RytinkiMM,Palvimo JJ. Analysis of androgen receptor activity by reporter gene assays. Methods Mol Biol. 2011;776:71-80.
29. Wang Q, Li W, Liu XS, et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell. 2007;27:380-392.
30. Rytinki MM, Palvimo JJ. SUMOylation attenuates the function of PGC-1alpha. J Biol Chem. 2009;284:26184-26193.
31. Rytinki MM, Kaikkonen S, Sutinen P, Palvimo JJ. Analysis of androgen receptor SUMOylation. Methods Mol Biol. 2011;776:183-197.
32. Paakinaho V, Kaikkonen S, Makkonen H, Benes V, Palvimo JJ. SUMOylation regulates the chromatin occupancy and anti-proliferative gene programs of glucocorticoid receptor. Nucleic Acids Res. 2014;42:1575-1592.
33. Golebiowski F, Matic I, Tatham MH, et al. System-wide changes to SUMO modifications in response to heat shock. Sci Signal. 2009; 2:ra24.
34. Mukherjee S, Cruz-Rodríguez O, Bolton E, Iniguez-Lluhi JA. The in vivo role of androgen receptor SUMOylation as revealed by androgen insensitivity syndrome and prostate cancer mutations targeting the proline/glycine residues of synergy control motifs. J Biol Chem. 2012;287:31195-31206.
35. Owerbach D, McKay EM, Yeh ET, Gabbay KH, Bohren KM. A proline-90 residue unique to SUMO-4 prevents maturation and sumoylation. Biochem Biophys Res Commun. 2005;337:517-520.
36. Yang F, Yao Y, Jiang Y, Lu L, Ma Y, Dai W. Sumoylation is important for stability, subcellular localization, and transcriptional activity of SALL4, an essential stem cell transcription factor. J Biol Chem. 2012;287:38600-38608.
37. Heun P. SUMOrganization of the nucleus. Curr Opin Cell Biol. 2007;19:350-355.
38. Mirosevich J, Gao N, Gupta A, Shappell SB, Jove R, Matusik RJ. Expression and role of Foxa proteins in prostate cancer. Prostate. 2006;66:1013-1028.
39. Robinson JL, Hickey TE, Warren AY, et al. Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype [published online December 2, 2013]. Oncogene. doi:10.1038/onc.2013.508.
40. Belaguli NS, Zhang M, Brunicardi FC, Berger DH. Forkhead box protein A2 (FOXA2) protein stability and activity are regulated by sumoylation. PLoS One. 2012;7:e48019.
41. Kotaja N, Karvonen U, Jänne OA, Palvimo JJ. The nuclear receptor interaction domain of GRIP1 is modulated by covalent attachment of SUMO-1. J Biol Chem. 2002;277:30283-30288.
42. Gao N, Zhang J, Rao MA, et al. The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol Endocrinol. 2003;17: 1484-1507.
43. Grasso CS, Wu YM, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487: 239-243.